Literature DB >> 11907190

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterization.

Danielle Gully1, Michel Geslin, Laurence Serva, Evelyne Fontaine, Pierre Roger, Christine Lair, Valerie Darre, Claudine Marcy, Pierre-Eric Rouby, Jacques Simiand, Josette Guitard, Georgette Gout, Regis Steinberg, Daniel Rodier, Guy Griebel, Philippe Soubrie, Marc Pascal, Rebecca Pruss, Bernard Scatton, Jean-Pierre Maffrand, Gerard Le Fur.   

Abstract

4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1- (3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a new 2-aminothiazole derivative, shows nanomolar affinity for human cloned or native corticotrophin-releasing factor (CRF)(1) receptors (pK(i) values of 8.73 and 9.08, respectively), and a 1000-fold selectivity for CRF(1) versus CRF(2 alpha) receptor and CRF binding protein. SSR125543A antagonizes CRF-induced stimulation of cAMP synthesis in human retinoblastoma Y 79 cells (IC(50) = 3.0 +/- 0.4 nM) and adrenocorticotropin hormone (ACTH) secretion in mouse pituitary tumor AtT-20 cells. SSR125543A is devoid of agonist activity in these models. Its brain penetration was demonstrated in rats by using an ex vivo [(125)I-Tyr(0)] ovine CRF binding assay. SSR125543A displaced radioligand binding to the CRF(1) receptor in the brain with an ID(50) of 6.5 mg/kg p.o. (duration of action >24 h). SSR125543A also inhibited the increase in plasma ACTH levels elicited in rats by i.v. CRF (4 microg/kg) injection (ID(50) = 1, 5, or 5 mg/kg i.v., i.p., and p.o., respectively); this effect lasted for more than 6 h when the drug was given orally at a dose of 30 mg/kg. SSR125543A (10 mg/kg p.o.) reduced by 73% the increase in plasma ACTH levels elicited by a 15-min restraint stress in rats. Moreover, SSR125543A (20 mg/kg i.p.) also antagonized the increase of hippocampal acetylcholine release induced by i.c.v. injection of 1 microg of CRF in rats. Finally, SSR125543A reduced forepaw treading induced by i.c.v. injection of 1 microg of CRF in gerbils (ID(50) = approximately 10 mg/kg p.o.). Altogether, these data indicate that SSR125543A is a potent, selective, and orally active CRF(1) receptor antagonist.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11907190     DOI: 10.1124/jpet.301.1.322

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

2.  V1b and CRHR1 receptor heterodimerization mediates synergistic biological actions of vasopressin and CRH.

Authors:  Brigitte Murat; Dominic Devost; Miriam Andrés; Julie Mion; Véra Boulay; Maithé Corbani; Hans H Zingg; Gilles Guillon
Journal:  Mol Endocrinol       Date:  2012-02-02

Review 3.  Pharmacogenetic approaches to the treatment of alcohol addiction.

Authors:  Markus Heilig; David Goldman; Wade Berrettini; Charles P O'Brien
Journal:  Nat Rev Neurosci       Date:  2011-10-20       Impact factor: 34.870

4.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

5.  Quantitative pharmacological analysis of antagonist binding kinetics at CRF1 receptors in vitro and in vivo.

Authors:  Simeon J Ramsey; Neil J Attkins; Rebecca Fish; Piet H van der Graaf
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 6.  Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models.

Authors:  John H Kehne; Christopher K Cain
Journal:  Pharmacol Ther       Date:  2010-09-06       Impact factor: 12.310

7.  Persistent anxiolytic affects after chronic administration of the CRF₁ receptor antagonist R121919 in rats.

Authors:  David A Gutman; Michael J Owens; K V Thrivikraman; Charles B Nemeroff
Journal:  Neuropharmacology       Date:  2010-10-14       Impact factor: 5.250

Review 8.  Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues.

Authors:  Markus Heilig; Annika Thorsell; Wolfgang H Sommer; Anita C Hansson; Vijay A Ramchandani; David T George; Daniel Hommer; Christina S Barr
Journal:  Neurosci Biobehav Rev       Date:  2009-11-24       Impact factor: 8.989

Review 9.  A key role for corticotropin-releasing factor in alcohol dependence.

Authors:  Markus Heilig; George F Koob
Journal:  Trends Neurosci       Date:  2007-07-16       Impact factor: 13.837

10.  CRF1 receptor antagonists do not reverse pharmacological disruption of prepulse inhibition in rodents.

Authors:  T N Douma; M J Millan; D Boulay; G Griebel; P M Verdouw; K G Westphal; B Olivier; L Groenink
Journal:  Psychopharmacology (Berl)       Date:  2013-11-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.